Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

15.08.2019 | short review Open Access

Systemic treatment of metastatic breast cancer: SABCS 2018

Zeitschrift:
memo - Magazine of European Medical Oncology
Autoren:
Theresa Westphal, Simon Peter Gampenrieder, MD Richard Greil
Wichtige Hinweise

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Summary

This review summarizes clinically relevant trials in metastatic breast cancer (MBC) presented at the 2018 San Antonio Breast Cancer Symposium (SABCS). At the meeting updates of two large phase III studies were presented: (1) the biomarker analysis of IMpassion130, trying to define the target population for the checkpoint inhibitor atezolizumab in triple-negative MBC and (2) a subgroup analysis of SOLAR-1, where the efficacy and safety of the alpha-specific Phosphoinositide 3(PI3)-kinase inhibitor alpelisib in combination with fulvestrant was investigated in patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2−) MBC. Furthermore, we review the results of a randomized phase II trial (CCTG MA38) comparing a continuous daily dosing of palbociclib to the standard treatment dose, and the phase 1b data of the B-cell lymphoma 2 (BCL-2) inhibitor venetoclax in combination with tamoxifen as a novel drug combination in patients with HR+/HER2−MBC.
Literatur
Über diesen Artikel